Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Portfolio Pulse from Vandana Singh
Ionis Pharmaceuticals Inc has entered an agreement with Roche Holdings AG for two early-stage programs for RNA-targeting investigational medicines for Alzheimer's and Huntington's diseases. Roche gains exclusive worldwide rights and will be responsible for clinical development, manufacturing, and commercialization. Ionis will receive a $60 million upfront payment from Roche and is eligible to receive development, regulatory, and commercial milestone payments and tiered royalties. Analysts see Ionis as the premier enterprise developing Antisense Oligonucleotides therapies but foresee near-term commercial headwinds.
September 27, 2023 | 5:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals has entered a partnership with Roche Holdings for two early-stage programs. The company will receive a $60 million upfront payment and is eligible for further payments.
The partnership with Roche Holdings and the upfront payment of $60 million, along with potential milestone payments, could provide a significant financial boost to Ionis Pharmaceuticals. However, analysts foresee near-term commercial headwinds.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Roche Holdings has gained exclusive worldwide rights for two early-stage programs from Ionis Pharmaceuticals and will be responsible for clinical development, manufacturing, and commercialization.
The partnership with Ionis Pharmaceuticals allows Roche Holdings to expand its portfolio with two early-stage programs. Roche will be responsible for clinical development, manufacturing, and commercialization, which could potentially boost its revenues in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100